Aurobindo Pharma Limited — JV/Acquisition, 09-02-2026: Amalgamation/Merger

Aurobindo Pharma's boards approved the merger of its wholly-owned step-down subsidiary Auro Vaccines Private Limited with wholly-owned subsidiary Curateq Biologics Private Limited. This strategic move aims to streamline group operations, optimize costs, and reduce regulatory compliance. For FY25, Curateq reported a turnover of INR 84.8 million (approx. 0.085 Cr), while Auro Vaccines had nil turnover. Since this is a merger between wholly-owned subsidiaries, there's no share swap or consideration, ensuring no change to Aurobindo Pharma's shareholding pattern.